School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
School of Pharmacy, Guizhou Medical University, Guian New District, 550025 Guizhou, China.
Bioorg Chem. 2021 Sep;114:105222. doi: 10.1016/j.bioorg.2021.105222. Epub 2021 Jul 28.
Seven new diterpenoids, eupholenes A-G (1-7), including two presegetanes (1 and 2), four jatrophanes (3-6), and one paraliane (7), along with 19 known analogues (8-26) were obtained by anti-liver fibrosis bioassay-guided isolation of Euphorbia sieboldiana. Their structures were elucidated by extensive spectroscopic data analyses, chemical methods, ECD calculations, and single-crystal X-ray diffractions. Euphorbesulin A (10), a presegetane diterpenoid (5/9/5 ring system), was identified as a promising anti-liver fibrosis agent that could inhibit the expressions of fibronectin (FN), α-smooth muscle actin (α-SMA), and collagen I in TGF-β1-stimulated LX-2 cells at a micromolar level. Mechanistic study revealed that 10 suppressed liver fibrosis via inhibition of TGF-β/Smad signaling pathway, and its potential target was TGF-β type I receptor. These findings suggested that presegetane diterpenoid could serve as a new type of structural motif in future anti-liver fibrosis drug development.
从Euphorbia sieboldiana 中通过抗肝纤维化生物测定指导分离得到了 7 种新的二萜类化合物,包括 2 种普西甾烷(1 和 2)、4 种 jatrophanes(3-6)和 1 种 paraliane(7),以及 19 种已知类似物(8-26)。通过广泛的光谱数据分析、化学方法、ECD 计算和单晶 X 射线衍射,确定了它们的结构。Euphorbesulin A(10),一种普西甾烷二萜类化合物(5/9/5 环系统),被鉴定为一种有前途的抗肝纤维化剂,能够在 TGF-β1 刺激的 LX-2 细胞中以微摩尔水平抑制纤连蛋白(FN)、α-平滑肌肌动蛋白(α-SMA)和胶原 I 的表达。机制研究表明,10 通过抑制 TGF-β/Smad 信号通路抑制肝纤维化,其潜在靶标是 TGF-β 型 I 受体。这些发现表明,普西甾烷二萜类化合物可以作为未来抗肝纤维化药物开发的新型结构基序。